<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243865</url>
  </required_header>
  <id_info>
    <org_study_id>PM005</org_study_id>
    <nct_id>NCT02243865</nct_id>
  </id_info>
  <brief_title>Chordate System Prophylactic Migraine Clinical Investigation</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Multi-center Pilot Study to Evaluate the Prophylactic Effect and Tolerability of Intranasal Kinetic Oscillation Stimulation (KOS) Using the Chordate System S200 in Patients Diagnosed With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chordate Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chordate Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to evaluate the performance of the Chordate System, in
      terms of the prophylactic effect and tolerability of treatment in patients diagnosed with
      migraine.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean frequency of migraine attacks per four weeks during the three months study duration after treatment compared to baseline</measure>
    <time_frame>From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean frequency of migraine attacks during the 1st, 2nd, and 3rd month and during the final four weeks of the three month study duration after treatment compared to baseline</measure>
    <time_frame>From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of migraine days per four weeks during the three months study duration after treatment compared to baseline</measure>
    <time_frame>From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of migraine days during the 1st, 2nd and 3rd month and during the final four weeks of the three month study duration after treatment compared to baseline</measure>
    <time_frame>From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)</time_frame>
    <description>&quot;Responder&quot; defined as a patient with 50% or greater reduction in migraine attack frequency after treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in median intensity of migraine pain over attacks during the three month study duration after treatment compared to baseline</measure>
    <time_frame>From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in median migraine duration in hours over attacks during the three month study duration after treatment compared to baseline</measure>
    <time_frame>From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drug consumption for acute treatment over attacks during the three month study duration after treatment compared to baseline</measure>
    <time_frame>From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction as measured on clinical global impression scales (CGI)</measure>
    <time_frame>At visit 4 day 98, ± 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease-specific quality of life from baseline to end of the three month study duration after treatment compared to baseline</measure>
    <time_frame>From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)</time_frame>
    <description>EQ-5D: 5 categorical dimensions and a VAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the frequency, severity, device-relationship and outcome of all adverse events at three months post treatment</measure>
    <time_frame>At visit 4 day 98, ± 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Chordate System S200 + CT100 (active treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chordate System S200 + CT100 (placebo treatment)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chordate System S200 + CT100 (active treatment)</intervention_name>
    <arm_group_label>Chordate System S200 + CT100 (active treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chordate System S200 + CT100 (placebo treatment)</intervention_name>
    <arm_group_label>Chordate System S200 + CT100 (placebo treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is legally competent, has been informed of the nature, the scope and the
             relevance of the study, voluntarily agrees to participation and the study's
             provisions, and has duly signed the Informed Consent Form (ICF).

          -  Male or female aged between 18 and 65 years

          -  Diagnosed as suffering from migraine with or without aura according to HIS
             classification (ICHD 3rd edition, beta version)

          -  Reported history of 3 to 8 migraine episodes per month during previous 2 months,
             confirmed during baseline

          -  Reported history of at least 48 hours of freedom from headache between migraine
             attacks, confirmed during baseline

          -  Onset of migraine headache occurred before age 50

          -  Reported history of migraine for more than one year

          -  Reported stable dose of prophylactic migraine medication(s), if any, during the two
             months prior to screening (visit 1), and willing and able to maintain stable dose(s)
             until the three months follow-up (visit 4)

        Exclusion Criteria:

          -  Meeting the ICHD criteria for medication overuse

          -  Reported history of 15 or more headache days per month (i.e. headaches of any kind),
             confirmed during baseline

          -  Reported frequency of non-migraine headaches exceeding 6 days per month, confirmed
             during baseline

          -  Unable to distinguish between migraine headaches and other headache types

          -  Treatment with Botox received within 6 months of the screening visit, or between the
             screening and treatment visits

          -  Ongoing treatment with implanted stimulator or other implanted device in the head
             and/or neck region

          -  Known pronounced anterior septal deviation, or other known relevant abnormality in the
             nasal cavity, including bacterial infection and wounds

          -  History of sinus surgery, transphenoidal surgery for pituitary or other lesions or CSF
             rhinorrhea

          -  Fitted with a pacemaker/defibrillator

          -  Previously treated with therapeutic radiation to the face (that could have influenced
             the nasal mucosa)

          -  Ongoing upper respiratory tract infection or a body temperature &gt;38.5°C (at
             treatment), or malignancy in the nasal cavity

          -  History of regular nose bleeding (epistaxis), or concomitant condition that could
             cause excessive bleeding, including treatment with the anticoagulant Varan

          -  Head injury or open wound that contraindicates use of Chordate Headband

          -  Known allergy to polyvinylchloride, a material used in the Catheter, or medicinal
             liquid paraffin

          -  Concurrent condition or risk of non-compliance that, in the investigator's opinion,
             may affect the interpretation of performance or safety data or which otherwise
             contraindicates participation in a clinical investigation

          -  Any change in migraine prophylaxis the previous two months

          -  Pregnant women

          -  Participation in a clinical research study within three months of enrolment or planned
             participation at any time during this clinical investigation

          -  Employees of the study site or the sponsor directly involved with the conduct of the
             study, or immediate family members or any such individuals

          -  Headache or migraine episode within the 48 hours prior to the first treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan-Åke Åkesson, MD</last_name>
    <email>jan-ake@stangablick.net</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vällingby</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2014</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 26, 2016</submitted>
    <returned>September 8, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

